Summary
Gilead Sciences, Inc. (GILD) filed its 2002 Annual Report, highlighting significant revenue growth driven by its HIV treatment, Viread, which saw a substantial increase in sales following its U.S. approval in late 2001 and EU approval in early 2002. The company also reported continued strong performance from its antifungal drug, AmBisome, though anticipating increased competition. Significant strategic moves include the acquisition of Triangle Pharmaceuticals in January 2003, aimed at bolstering its antiviral pipeline, and the sale of its oncology assets to OSI Pharmaceuticals in late 2001 to sharpen its focus on infectious diseases. Gilead is actively managing its financial resources, including issuing convertible notes to strengthen its liquidity, while also navigating the complexities of global regulatory environments and international credit risks.
Key Highlights
- 1Viread sales experienced a significant surge, contributing 53% of total product sales in 2002, a dramatic increase from 8% in 2001, driven by recent approvals and market expansion.
- 2AmBisome sales grew 13% in 2002, maintaining its position as a key revenue driver, though the company anticipates future competition and a slight decline in sales for 2003.
- 3The acquisition of Triangle Pharmaceuticals in January 2003 is a key strategic move to enhance the company's antiviral drug development pipeline.
- 4Gilead divested its oncology assets to OSI Pharmaceuticals in December 2001, allowing for a strategic focus on infectious diseases.
- 5The company's total revenue more than doubled from $233.8 million in 2001 to $466.8 million in 2002.
- 6Gilead issued $345.0 million in 2% convertible senior notes in December 2002 to bolster its capital resources.
- 7The company maintains a strong cash position, with cash, cash equivalents, and marketable securities totaling $942.4 million at the end of 2002.